Each week, the AUA publishes weekly updates on the lasted insurance issues pertaining to urology. This week’s update includes information on Aetna’s revision to its Erectile Dysfunction medical policy, as well as Blue Cross BlueShield of Alabama’s Prostatic Urethral Lift medical policy change.
Erectile Dysfunction (ED): Aetna has revised its Erectile Dysfunction Policy to state that the following are considered experimental and investigational:
botulinum toxin for the treatment of ED; and
the use of serum biomarkers (e.g., E-selectin, endothelial progenitor cells, endothelial micro-particles, interleukin-10, malondialdehyde, nitric oxide, ...